FeesSafety
Pluang+

NeurAxis posts 150% revenue growth in Q3 2026, boosted by new insurance coverage and FDA approvals

Company Fundamentals
09 Nov 2026, 14:05 WIB
GlobeNewsWire
View Source
Bullish
NeurAxis posts 150% revenue growth in Q3 2026, boosted by new insurance coverage and FDA approvals

NeurAxis reported a 150% year-over-year revenue increase to $2.0 million in Q3 2026, driven by expanded insurance coverage following the Category I CPT code effective January 2026 and FDA clearance for its IB-Stim device. Unit deliveries rose 92%, and gross margin improved by 330 basis points due to more full-price sales. The company secured major insurer coverage for over 147 million lives and a Veterans Affairs contract, positioning for further growth. Despite a net loss of $6.5 million due to stock compensation expenses, NeurAxis is investing in commercial expansion and expects continued revenue growth.

NeurAxis' record Q3 2026 financial results provide context for health sector market activity. For readers following health stocks, here is Pluang's market snapshot as of Nov 09, 2026 18:41 WIB: Among 150 priced US health-sector stocks, 108 rose and 26 fell today. Notable movers include Heron Therapeutics Inc (HRTX) up 33.46% at USD 0.38 with a typical hold time of 39 days, Inovio Pharmaceuticals Inc (INO) up 11.93% at USD 1.36 with a 41-day hold, and Cassava Sciences Inc (FLNA) up 6.01% at USD 0.48 with a 39-day hold.

More News

Microsoft to retire UWP Map Control by Nov 2026; OnTerra offers ready replacement using Azure Maps.

Microsoft to retire UWP Map Control by Nov 2026; OnTerra offers ready replacement using Azure Maps.

Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...

Market News
Neutral
1 hour ago
New combo therapy shows promise in tough metastatic breast cancer cases with high response rates

New combo therapy shows promise in tough metastatic breast cancer cases with high response rates

Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...

Company Fundamentals
Bullish
2 hours ago
Deadlines set for lead plaintiff appointments in class action lawsuits against Ensign, Netcapital, and Webull.

Deadlines set for lead plaintiff appointments in class action lawsuits against Ensign, Netcapital, and Webull.

Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...

Bearish
2 hours ago
Octave launches Attune Facilities, an AI-driven tool for managing complex multi-site operations efficiently.

Octave launches Attune Facilities, an AI-driven tool for managing complex multi-site operations efficiently.

Octave Intelligence plc has introduced Octave Attune Facilities, a cloud-based software solution designed to help organizations manage multiple sites with AI-powered tools. This platform integrates building, space, maintenance, and operational data t...

Market News
Bullish
2 hours ago
ITT Inc. price target raised to $259 after strong Q3 with 44% revenue growth and 20% earnings rise.

ITT Inc. price target raised to $259 after strong Q3 with 44% revenue growth and 20% earnings rise.

ITT Inc. reported a strong third quarter with revenue up 44% to over $1.40 billion and adjusted earnings rising 20% to $2.26 per share, driven by the SPX FLOW acquisition and 8% organic growth. Orders surged 58%, supported by aerospace, defense, and ...

Analyst Insights
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App